VENTURA COUNTY
HEALTH CARE PLAN

Adriamycin (doxorubicin)

Effective Date: 10/22/13

Date Developed: 9/3/13 by Albert Reeves MD

Last Approval Date 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20, 8/3/21, 2/1/22, 1/31/23, 2/13/24, 2/18/25

Adriamycin inhibits nucleotide replication and the action of DNA and RNA polymerases via nucleotide base intercalation (a form of substitution).

Prior Authorization Criteria:

Labeled Indications:

Breast cancer, adjuvant therapy: Treatment component of adjuvant therapy (multi-agent) in women with evidence of axillary lymph node involvement following resection of primary breast cancer

Other cancers: Treatment of acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer (transitional cell, metastatic), bone sarcoma (metastatic), breast cancer (metastatic), bronchogenic carcinoma (metastatic), Hodgkin lymphoma, non-Hodgkin lymphomas, neuroblastoma (metastatic), ovarian cancer (metastatic), soft tissue sarcoma (metastatic), thyroid carcinoma (metastatic), Wilms tumor (metastatic).

Adrenocortical carcinoma, advanced; Adult T-cell leukemia/lymphoma; Endometrial carcinoma; Hepatocellular carcinoma, intermediate stage, chemoembolization; Hepatocellular carcinoma, metastatic; Multiple myeloma; Neuroendocrine tumors, pancreatic; Renal carcinoma, advanced; Salivary gland cancers, advanced; Thymomas and thymic malignancies; Uterine sarcoma; Waldenström macroglobulinemia

Note: **See VCHCP Policy for Prescription Medication for Off-Label Use for details.**

Dosage: **Usual or typical adult dosages:** I.V.: - 30-75 mg/m^2/dose

Usual/typical pediatric dosages: I.V.: - 25-75 mg/m^2/dose

Note: Refer to product literature for specific dosing protocols for each disease and for hepatic impairment

Note: Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing

Dosing: Adjustment for Toxicity
The following delays and/or dose reductions have been used:
Neutropenic fever/infection: Consider reducing to 75% of dose in subsequent cycles ANC $<1000/mm^3$: Delay treatment until ANC recovers to $\geq 1000/mm^3$
Platelets $<100,000/mm^3$: Delay treatment until platelets recover to $\geq 100,000/mm^3$

How Supplied: 2mg/mL (5, 10, 25, 100 mL)

Precautions: acute and chronic cardiotoxicity (dysrhythmias, CHF); neutropenia; thrombocytopenia; alopecia; secondary malignancy (AML, MDS); myelosuppression; severe tissue damage from extravasation; several drug interactions; may increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver; children are at increased risk for developing delayed cardiotoxicity

References:

1. Berg SL, Grisell DL, DeLaney TF, et al, "Principles of Treatment of Pediatric Solid Tumors," *Pediatr Clin North Am*, 1991, 38(2):249-67. [PubMed 2006077]
2. Brown JR and Iman SH, "Recent Studies on Doxorubicin and Its Analogues," *Prog Med Chem*, 1984, 21:169-236. [PubMed 6400135]
3. Cummings J and Smyth JF, "Pharmacology of Adriamycin: The Message to the Clinician," *Eur J Cancer Clin Oncol*, 1988, 24(4):579-82. [PubMed 3289943]
4. Curran CF, "Acute Doxorubicin Overdoses," *Ann Intern Med*, 1991, 115(11):913-4.
5. Curran CF and Luce JK, "Accidental Acute Exposure to Doxorubicin," *Cancer Nurs*, 1989, 12(6):329- 31. [PubMed 2590899]
6. Davis HL and Davis TE, "Daunorubicin and Adriamycin in Cancer Treatment: An Analysis of Their Roles and Limitations," *Cancer Treat Rep*, 1979, 63(5):809-15. [PubMed 378369]
7. Floyd J, Mirza I, Sachs B, et al, "Hepatotoxicity of Chemotherapy," *Semin Oncol*, 2006, 33(1):50-67.[PubMed 16473644]
8. Floyd JD, Nguyen DT, Lobins RL, et al, "Cardiotoxicity of Cancer Therapy," *J Clin Oncol*, 2005, 23(30):7685-96. [PubMed 16234530]
9. Gordon KB, Tajuddin A, Guitart J, et al, "Hand-Foot Syndrome Associated With Liposome-Encapsulated Doxorubicin Therapy," *Cancer*, 1995, 75(8):2169-73. [PubMed 7697608]
10. Griggs JJ, Mangu PB, Anderson H, et al, "Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline," *J Clin Oncol*, 2012, 30(13):1553-61. [PubMed 22473167]
11. Ishii E, Hara T, Ohkubo K, et al, "Treatment of Childhood Acute Lymphoblastic Leukemia With Intermediate Dose Cytosine Arabinoside and Adriamycin," *Med Pediatr Oncol*, 1986, 14(2):73-7. [PubMed 3458999]
12. King PD and Perry MC, "Hepatotoxicity of Chemotherapy," *Oncologist*, 2001, 6(2):162-76. [PubMed 11306728]
13. Lauvin R, Miglianico L, and Hellegouarc'h R, "Skin Cancer Occurring 10 Years After the Extravasation of Doxorubicin," *N Engl J Med*, 1995, 332(11):754.
14. Legha SS, Benjamin RS, Mackay B, et al, "Reduction of Doxorubicin Cardiotoxicity by Prolonged

Continuous Intravenous Infusion," *Ann Intern Med*, 1982, 96(2):133-9. [PubMed 7059060]
15. Morgan C, Tillett T, Braybrooke J, et al, "Management of Uncommon Chemotherapy-Induced Emergencies," *Lancet Oncol*, 2011, 12(8):806-14. [PubMed 21276754]
16. Namer M, "Anthracyclines in the Adjuvant Treatment of Breast Cancer," *Drugs*, 1993, 45(Suppl 2):4-9. [PubMed 7693421]
17. National Comprehensive Cancer Network® (NCCN), "Clinical Practice Guidelines in Oncology™: Breast Cancer," Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
18. National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf. Accessed January 21, 2013.
19. Seifert CF, Nesser ME, and Thompson DF, "Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity," *Ann Pharmacother*, 1994, 28(9):1063-72. [PubMed 7803884]
20. Speth PA, van Hoesel QG, and Haanen C, "Clinical Pharmacokinetics of Doxorubicin," *Clin Pharmacokinet*, 1988, 15(1):15-31. [PubMed 3042244]
21. Speyer JL, Green MD, Kramer E, et al, "Protective Effect of the Bispiperazinedione ICRF-187 Against Doxorubicin-Induced Cardiac Toxicity in Women With Advanced Breast Cancer," *N Engl J Med*, 1988, 319(12):745-52. [PubMed 3137469]
22. Adriamycin (doxorubicin) injection, USP [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2022.23 Doxorubicin [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; November 2022.
24 Suto H, Suto M, Inui Y, Okamura A. Late-onset doxorubicin-induced congestive heart failure in an elderly cancer survivor: a case report. Front Cardiovasc Med. 2023;10:1124276. doi:10.3389/fcvm.2023.1124276

Revision History:
Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 6/29/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20
Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 8/3/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22
Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/31/23
Date Reviewed/No Updates: 2/13/24 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/13/24
Date Reviewed/Updated: 2/18/25 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/25

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Dosage and Precautions section updated
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/18/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Removed Prior authorization criteria and added Labeled Indication section, changed the word “Unlabeled” to “Off-Label.”